A subcutaneous insulin pharmacokinetic model for computer simulation in a diabetes decision support role: Model structure and parameter identification

Journal of Diabetes Science and Technology

Volumn 2, Issue 4, 2008, Pages 658-671

  Wong, Jason ^a   Chase, J Geoffrey ^a   Hann, Christopher E ^a   Shaw, Geoffrey M ^b   Lotz, Thomas F ^a   Lin, Jessica ^a   Le Compte, Aaron J ^a  

^a UNIVERSITY OF CANTERBURY   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Blood glucose; Compartmental models; Decision support; Diabetes; Hyperglycemia; Insulin; Simulation; Subcutaneous injection

Indexed keywords

EID: 80051586486     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680800200417     Document Type: Article

References (67)

1. Binder C. Absorption of injected insulin. A clinical-pharmacological study. Acta Pharmacol Toxicol (Copenh). 1969;27 Suppl 2:1-84.
2. Berger M, Cüppers HJ, Hegner H, Jörgens V, Berchtold P. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care. 1982;5(2):77-91.
3. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care. 1984;7(2):188-99.
4. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL. Factors infuencing the absorption, serum-insulin concentration, and blood-glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care. 1981;4(3):366-76.
5. Koivisto VA, Fortney S, Hendler R, Felig P. A rise in ambient temperature augments insulin absorption in diabetic patients. Metabolism. 1981;30(4):402-5.
6. Kølendorf K, Bojsen J, Nielsen SL. Adipose tissue blood fow and insulin disappearance from subcutaneous tissue. Clin Pharmacol Ther. 1979;25(5 Pt 1):598-604.
7. Koivisto VA, Felig P. Effects of leg exercise on insulin absorption in diabetic patients. N Engl J Med. 1978;298(2):79-83.
8. Klemp P, Staberg B, Madsbad S, Kølendorf K. The insulin absorption from subcutaneous tissue in smoking diabetic. Acta Endocrinol. 1982;100:37.
9. Klemp P, Staberg B, Madsbad S, Kølendorf K. Smoking reduces insulin absorption from subcutaneous tissue. Br Med J (Clin Res Ed). 1982;284(6311):237.
10. Hildebrandt P, Sestoft L, Nielsen SL. The absorption of subcutaneously injected short-acting soluble insulin: Influence of injection technique and concentration. Diabetes Care. 1983;6(5):459-62.
11. de Meijer PH, Lutterman JA, van Lier HJ, van't Laar A. The variability of the absorption of subcutaneously injected insulin: effect of injection technique and relation with brittleness. Diabet Med. 1990;7(6):499-505.
12. Hildebrandt P. Subcutaneous absorption of insulin in insulindependent diabetic patients. Influence of species, physicochemical properties of insulin and physiological factors. Dan Med Bull. 1991;38(4):337-46.
13. Mosekilde E, Jensen KS, Binder C, Pramming S, Thorsteinsson B. Modeling absorption kinetics of subcutaneous injected soluble insulin. J Pharmacokinet Biopharm. 1989;17(1):67-87.
14. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care. 1998;21(11):1910-4.
15. Lehmann ED, Deutsch T. A physiological model of glucoseinsulin interaction in type 1 diabetes mellitus. J Biomed Eng. 1992;14(3):235-42.
16. Hovorka R, Canonico V, Chassin LJ, Haueter U, Massi-Benedetti M, Orsini Federici M, Pieber TR, Schaller HC, Schaupp L, Vering T, Wilinska ME. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas. 2004;25(4):905-20.
17. Shimoda S, Nishida K, Sakakida M, Konno Y, Ichinose K, Uehara M, Nowak T, Shichiri M. Closed-loop subcutaneous insulin infusion algorithm with a short-acting insulin analog for long-term clinical application of a wearable artificial endocrine pancreas. Front Med Biol Eng. 1997;8(3):197-211.
18. Andreassen S, Benn JJ, Hovorka R, Olesen KG, Carson ER. A probabilistic approach to glucose prediction and insulin dose adjustment: description of metabolic model and pilot evaluation study. Comput Methods Programs Biomed. 1994;41(3-4):153-65.
19. Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, Draeger E. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6):1614-20.
20. Guerci B, Sauvanet J P. Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metab. 2005;31(4 Pt 2):4S7-4S24.
21. Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia. 2005;48(10):1988-95.
22. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002;4(5):673-82.
23. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49(12):2142-8.
24. Evans JM, Newton RW, Ruta DA, MacDonald TM, Stevenson RJ, Morris AD. Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. BMJ. 1999;319(7202):83-6.
25. Schütt M, Kern W, Krause U, Busch P, Dapp A, Grziwotz R, Mayer I, Rosenbauer J, Wagner C, Zimmermann A, Kerner W, Holl RW; DPV Initiative. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24, 500 patients from 191 centers in Germany and Austria. Exp Clin Endocrinol Diabetes. 2006;114(7):384-8.
26. Berger M, Rodbard D. Computer simulation of plasma insulin and glucose dynamics after subcutaneous insulin injection. Diabetes Care. 1989;12(10):725-36.
27. Lehmann ED. AIDA: a computer-based interactive educational diabetes simulator. Diabetes Educ. 1998;24:341.
28. Kobayashi T, Sawano S, Itoh T, Kosaka K, Hirayama H, Kasuya Y. The pharmacokinetics of insulin after continuous subcutaneous infusion or bolus subcutaneous injection in diabetic patients. Diabetes. 1983;32(4):331-6.
29. Kraegen EW, Chisholm DJ. Insulin responses to varying profiles of subcutaneous insulin infusion: kinetic modelling studies. Diabetologia. 1984;26(3):208-13.
30. Furler SM, Kraegen EW. Quantitative aspects of subcutaneous insulin absorption. Diabet Med. 1989;6(8):657-65.
31. Puckett WR, Lightfoot EN. A model for multiple subcutaneous insulin injections developed from individual diabetic patient data. Am J Physiol. 1995;269(6 Pt 1):E1115-24.
32. Kang S, Brange J, Burch A, Vølund A, Owens DR. Subcutaneous insulin absorption explained by insulin's physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care. 1991;14(11):942-8.
33. Wilinska ME, Chassin LJ, Schaller HC, Schaupp L, Pieber TR, Hovorka R. Insulin kinetics in type-1 diabetes: continuous and bolus delivery of rapid acting insulin. IEEE Trans Biomed Eng. 2005;52(1):3-12.
34. Pham M. Diabetes: proprietary survey on insulin pumps and continuous blood glucose monitoring. New York: HSBC Securities (USA) Inc.; 2005.
35. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta, GA: U. S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2005.
36. Lehmann ED, Deutsch T. AIDA2: A Mk. II automated insulin dosage advisor. J Biomed Eng. 1993;15:201-11.
37. Trajanoski Z, Wach P, Kotanko P, Ott A, Skraba F. Pharmacokinetic model for the absorption of subcutaneously injected soluble insulin and monomeric insulin analogs. Biomed Tech (Berl). 1993;38(9):224-31.
38. Tarín C, Teufel E, Picó J, Bondia J, Pfeiderer HJ. Comprehensive pharmacokinetic model of insulin glargine and other insulin formulations. IEEE Trans Biomed Eng. 2005;52(12):1994-2005.
39. Nucci G, Cobelli C. Models of subcutaneous insulin kinetics. A critical review. Comput Methods Programs Biomed. 2000;62(3):249-57.
40. Carson ER, Cobelli C. Modelling methodology for physiology and medicine. San Diego: Academic Press; 2001.
41. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, Melberg SG, Norris F, Norris K, Snel L, et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature. 1988;333(6174):679-82.
42. Brange J, Owens DR, Kang S, Vølund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care. 1990;13(9):923-54.
43. Blundell TL, Dodson G, Hodgkin D, Mercola D. Insulin: the structure in the crystal and its refection in chemistry and biology. Adv Protein Chem. 1972;26:279-402.
44. Emdin SO, Dodson GG, Cutfield JM, Cutfield SM. Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell. Diabetologia. 1980;19(3):174-82.
45. Gin H, Hanaire-Broutin H. Reproducibility and variability in the action of injected insulin. Diabetes Metab. 2005;31(1):7-13.
46. Brange J, Vølund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev. 1999;35(2-3):307-335.
47. Gerich JE. Insulin glargine: long-acting basal insulin analog for improved metabolic control. Curr Med Res Opin. 2004;20(1):31-7.
48. Campbell RK, White JR, Levien T, Baker D Insulin glargine. Clin Ther. 2001;23(12):1938-57.
49. Woodworth J, Howey D, Bowsher R, Lutz S, Santa P, Brady P. [Lys (B28), Pro (B29) ] human insulin (K)-dose-ranging vs humulin R (H). Diabetes. 1993;42:A54.
50. Kaku K, Matsuda M, Urae A, Irie S. Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. Diabetes Res Clin Pract. 2000;49(2-3):119-26.
51. Chase JG, Shaw GM, Lin J, Doran CV, Hann C, Robertson MB, Browne PM, Lotz T, Wake GC, Broughton B. Adaptive bolus-based targeted glucose regulation of hyperglycaemia in critical care. Med Eng Phys. 2005;27(1):1-11.
52. Clausen WH, De Gaetano A, Vølund A. Within-patient variation of the pharmacokinetics of subcutaneously injected biphasic insulin aspart as assessed by compartmental modelling. Diabetologia. 2006;49(9):2030-8.
53. Heinemann L, Anderson JH Jr. Measurement of insulin absorption and insulin action. Diabetes Technol Ther. 2004;6(5):698-718.
54. Wong XW, Singh-Levett I, Hollingsworth LJ, Shaw GM, Hann CE, Lotz T, Lin J, Wong OS, Chase JG. A novel, model-based insulin and nutrition delivery controller for glycemic regulation in critically ill patients. Diabetes Technol Ther. 2006;8(2):174-90.
55. Chase JG, Shaw GM, Lin J, Doran CV, Bloomfield M, Wake GC, Broughton B, Hann C, Lotz T. Impact of insulin-stimulated glucose removal saturation on dynamic modelling and control of hyperglycaemia. IJISTA. 2004;1:79-94.
56. Hann CE, Chase JG, Lin J, Lotz T, Doran CV, Shaw GM. Integralbased parameter identification for long-term dynamic verification of a glucose-insulin system model. Comput Methods Programs Biomed. 2005;77(3):259-70.
57. Plank J, Wutte A, Brunner G, Siebenhofer A, Semlitsch B, Sommer R, Hirschberger S, Pieber TR. A direct comparison of insulin analogs aspart and lispro in type 1 diabetic patients. Diabetes Care. 2002;25(11):2053-7.
58. Hedman CA, Lindström T, Arnqvist HJ. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care. 2001;24(6):1120-1.
59. von Mach MA, Brinkmann C, Hansen T, Weilemann LS, Beyer J. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp Clin Endocrinol Diabetes. 2002;110(8):416-9.
60. Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I. Comparison of pharmacokinetic and pharmacodynamic properties of singledose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Clin Ther. 2004;26(12):2084-91.
61. Kang S, Creagh FM, Peters JR, Brange J, Vølund A, Owens DR. Comparison of subcutaneous soluble human insulin and insulin analogs (Aspb9, Glub27-Aspb10-Aspb28) on meal-related plasmaglucose excursions in type I diabetic subjects. Diabetes Care. 1991;14(7):571-7.
62. Hübinger A, Weber W, Jung W, Wehmeyer K, Gries FA. The pharmacokinetics of two different concentrations of shortacting insulin, intermediate-acting insulin, and an insulin mixture following subcutaneous injection. Clin Investig. 1992;70(7):621-6.
63. Davis SN, Thompson CJ, Brown MD, Home PD, Alberti KG. A comparison of the pharmacokinetics and metabolic effects of human regular and NPH insulin mixtures. Diabetes Res Clin Pract. 1991;13(1-2):107-17.
64. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the Influence of different subcutaneous injection sites. Diabetes Care. 2000;23(6):813-9.
65. Bottermann P, Gyaram H, Wahl K, Ermler R, Lebender A. Insulin concentrations and time-action profiles of three different intermediate-acting insulin preparations in nondiabetic volunteers under glucose-controlled glucose infusion technique. Diabetes Care. 1982;5 Suppl 2:43-52.
66. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23(5):644-9.
67. Owens DR, Vora JP, Heding LG, Luzio S, Ryder RE, Atiea J, Hayes TM. Human, porcine and bovine ultralente insulin: subcutaneous administration in normal man. Diabet Med. 1986;3(4):326-9.